{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:58:16Z","timestamp":1791907096187,"version":"4.3.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000858","name":"University of Sheffield","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cerebellum"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune-mediated ataxias account for a substantial number of sporadic otherwise idiopathic ataxias. Despite some well-characterised entities such as paraneoplastic cerebellar degeneration where diagnostic markers exist, the majority of immune ataxias remained undiagnosed and untreated. We present here our experience in the treatment of suspected primary autoimmune cerebellar ataxia (PACA) using mycophenolate. All patients reported attend the Sheffield Ataxia Centre on a regular basis and had undergone extensive investigations, including genetic testing using next-generation sequencing, with other causes of ataxia excluded. The diagnosis of PACA was strongly suspected based on investigations, pattern of disease progression, and cerebellar involvement. Patients were treated with mycophenolate and monitored using MR spectroscopy of the cerebellar vermis. Thirty patients with PACA are reported here. Of these, 22 received mycophenolate (group 1). The remaining 8 were not on treatment (group 2-control group). Out of the 22 treated patients, 4 underwent serial MR spectroscopy prior to starting treatment and thus were used as controls making the total number of patients in the control group 12. The mean change of the MRS within the vermis (NAA\/Cr area ratio) in the treatment group was +\u20090.144\u2009\u00b1\u20090.09 (improved) and in the untreated group \u2212\u20090.155\u2009\u00b1\u20090.06 (deteriorated). The difference was significant. We also demonstrated a strong correlation between the spectroscopy and the SARA score. We have demonstrated the effectiveness of mycophenolate in the treatment of PACA. The results suggest that immune-mediated ataxias are potentially treatable, and that there is a need for early diagnosis to prevent permanent neurological deficit. The recently published diagnostic criteria for PACA would hopefully aid the diagnosis and treatment of this entity.<\/jats:p>","DOI":"10.1007\/s12311-020-01152-4","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T09:03:02Z","timestamp":1591779782000},"page":"680-684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Treatment of Primary Autoimmune Cerebellar Ataxia with Mycophenolate"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2542-8954","authenticated-orcid":false,"given":"M.","family":"Hadjivassiliou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Grunewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. D.","family":"Shanmugarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. G.","family":"Sarrigiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Skarlatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hoggard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"1152_CR1","first-page":"8","volume":"9","author":"M Hadjivassiliou","year":"2010","unstructured":"Hadjivassiliou M. Primary autoimmune cerebellar ataxia (PACA). Adv Clin Neurosci Rehabil. 2010;9:8\u201311.","journal-title":"Adv Clin Neurosci Rehabil"},{"key":"1152_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1136\/jnnp-2016-314863","volume":"88","author":"M Hadjivassiliou","year":"2016","unstructured":"Hadjivassiliou M, Martindale J, Shanmugarajah P, Gr\u00fcnewald RA, Sarrigiannis PG, Beauchamp N, et al. Causes of progressive cerebellar ataxia: prospective evaluation of 1500 patients. J Neurol Neurosurg Psychiatry. 2016;88:301\u20139. https:\/\/doi.org\/10.1136\/jnnp-2016-314863.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1152_CR3","doi-asserted-by":"publisher","unstructured":"Hadjivassiliou M, Graus F, Honnorat J, et al. Diagnostic criteria for primary autoimmune cerebellar ataxiA-guidelines from an International Task Force on Immune-Mediated Cerebellar Ataxias. Cerebellum. 2020. https:\/\/doi.org\/10.1007\/s12311-020-01132-8.","DOI":"10.1007\/s12311-020-01132-8"},{"key":"1152_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0000000000004237","volume":"89","author":"M Hadjivassiliou","year":"2017","unstructured":"Hadjivassiliou M, Grunewald RA, Sanders DS, Shanmugarajah P, Hoggard N. Effect of gluten-free diet on MR spectroscopy in gluten ataxia. Neurology. 2017;89:1\u20135.","journal-title":"Neurology"},{"key":"1152_CR5","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3390\/nu10101444","volume":"10","author":"M Hadjivassiliou","year":"2018","unstructured":"Hadjivassiliou M, Grunewald RA, Sanders DS, et al. The significance of low titre antigliadin antibodies in the diagnosis of gluten ataxia. Nutrients. 2018;10:1444. https:\/\/doi.org\/10.3390\/nu10101444.","journal-title":"Nutrients"},{"key":"1152_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.autrev.2006.11.001","volume":"6","author":"L Iaccarino","year":"2007","unstructured":"Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Putticic P, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev. 2007;6:190\u20135.","journal-title":"Autoimmun Rev"},{"issue":"10","key":"1152_CR7","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/mds.22129","volume":"23","author":"M Hadjivassiliou","year":"2008","unstructured":"Hadjivassiliou M, Boscolo S, Tongiorgi E, et al. Cerebellar ataxia as a possible organ specific autoimmune disease. Mov Disord. 2008;23(10):1270\u2013377.","journal-title":"Mov Disord"},{"key":"1152_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40673-015-0034-y","volume":"2","author":"H Mitoma","year":"2015","unstructured":"Mitoma H, Hadjivassiliou M, Honnorat J. Guidelines for treatment of immune-mediated cerebellar ataxias. Cerebellum & Ataxias. 2015;2:14. https:\/\/doi.org\/10.1186\/s40673-015-0034-y.","journal-title":"Cerebellum & Ataxias"},{"key":"1152_CR9","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2015.2378","volume":"72","author":"AL Jones","year":"2015","unstructured":"Jones AL, Flanagan EP, Pittock SJ, Mandrekar JN, Eggers SD, Ahlskog JE, et al. Responses to and outcomes of treatment of autoimmune cerebellar ataxia in adults. JAMA Neurol. 2015;72:1304\u201312.","journal-title":"JAMA Neurol"},{"key":"1152_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jneuroim.2019.01.002","volume":"330","author":"X Xu","year":"2019","unstructured":"Xu X, Ren H, Li L, Wang J, Fechner K, Guan H. Anti-Homer-3 antibody associated cerebellar ataxia: a rare case report and literature review. J Neuroimmunol. 2019;330:155\u20138.","journal-title":"J Neuroimmunol"},{"key":"1152_CR11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s12311-019-01048-y","volume":"18","author":"Z Weihua","year":"2019","unstructured":"Weihua Z, Haitao R, Fang F, Xunzhe Y, Jing W, Hongzhi G. Neurochondrin antibody serum positivity in three cases of autoimmune cerebellar ataxia. Cerebellum. 2019;18:1137\u201342.","journal-title":"Cerebellum"},{"key":"1152_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0000000000009242","volume":"94","author":"F Han","year":"2020","unstructured":"Han F, Ren H, Tang M, Zhu Y, Guan H. Clinical reasoning: a 47-year old man with rapidly progressive ataxia and vitiligo. Neurology. 2020;94:1\u20136.","journal-title":"Neurology"},{"issue":"4","key":"1152_CR13","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1016\/j.neurad.2012.08.003","volume":"40","author":"M Hadjivassiliou","year":"2013","unstructured":"Hadjivassiliou M, Currie S, Hoggard N. MR spectroscopy in paraneoplastic cerebellar degeneration. J Neuroradiol. 2013 Oct;40(4):3310.","journal-title":"J Neuroradiol"},{"key":"1152_CR14","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.clinph.2018.03.026","volume":"129","author":"DJ Blackburn","year":"2018","unstructured":"Blackburn DJ, Forbes M, Unwin Z, Hoggard N, Hadjivassiliou M, Sarrigiannis PG. Exaggerated startle in post-infectious opsoclonus myoclonus syndrome. Clin Neurophysiol. 2018;129:1372\u20133.","journal-title":"Clin Neurophysiol"},{"key":"1152_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40673-015-0021-3","volume":"2","author":"RD Sandler","year":"2015","unstructured":"Sandler RD, Hoggard N, Hadjivassiliou M. Miller-fisher syndrome: is the ataxia central or peripheral? Cerebellum Ataxias. 2015;2:3. https:\/\/doi.org\/10.1186\/s40673-015-0021-3.","journal-title":"Cerebellum Ataxias"},{"key":"1152_CR16","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/mds.23067","volume":"25","author":"G Oz","year":"2010","unstructured":"Oz G, Hutter D, Tkac I, et al. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov Disord. 2010;25:1253\u201361.","journal-title":"Mov Disord"}],"container-title":["The Cerebellum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-020-01152-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-020-01152-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-020-01152-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T08:19:56Z","timestamp":1625127596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12311-020-01152-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1152"],"URL":"https:\/\/doi.org\/10.1007\/s12311-020-01152-4","relation":{},"ISSN":["1473-4222","1473-4230"],"issn-type":[{"value":"1473-4222","type":"print"},{"value":"1473-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"10 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This report is based on a retrospective observational case series of patients regularly attending the Sheffield Ataxia Centre. The South Yorkshire Research Ethics Committee has confirmed that no ethical approval is indicated given that all investigations\/interventions were clinically indicated and did not form part of a research study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The views expressed are those of the authors and not necessarily those of the BRC, NHS, the NIHR, or the Department of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}